Kevin O Saunders
Overview
Explore the profile of Kevin O Saunders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
4562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Design of SARS-CoV-2 RBD Immunogens to Focus Immune Responses Towards Conserved Coronavirus Epitopes
Harris C, Kapingidza A, San J, Christopher J, Gavitt T, Rhodes B, et al.
bioRxiv
. 2025 Jan;
PMID: 39829739
SARS-CoV-2 continues to evolve, with new variants emerging that evade pre-existing immunity and limit the efficacy of existing vaccines. One approach towards developing superior, variant-proof vaccines is to engineer immunogens...
2.
Swanson O, Zhang Q, Van Itallie E, Tian M, Brown A, Harris C, et al.
Sci Transl Med
. 2025 Jan;
17(780):eadr2218.
PMID: 39772772
Elicitation of HIV broadly neutralizing antibodies (bnAbs) by vaccination first requires the activation of diverse precursors, followed by successive boosts that guide these responses to enhanced breadth through the acquisition...
3.
May A, Lella M, Lindenberger J, Berkman A, Kumar U, Dutta M, et al.
bioRxiv
. 2024 Dec;
PMID: 39713338
Henipaviruses, a genus within the family, include the highly virulent Nipah and Hendra viruses that cause reoccurring outbreaks of deadly disease . Recent discoveries of several new species, including the...
4.
Holmes S, Li H, Shen X, Martin M, Tuck R, Chen Y, et al.
Nat Commun
. 2024 Nov;
15(1):10302.
PMID: 39604409
The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in...
5.
Henderson R, Anasti K, Manne K, Stalls V, Saunders C, Bililign Y, et al.
Nat Commun
. 2024 Nov;
15(1):9503.
PMID: 39489734
Vaccine development targeting rapidly evolving pathogens such as HIV-1 requires induction of broadly neutralizing antibodies (bnAbs) with conserved paratopes and mutations, and in some cases, the same Ig-heavy chains. The...
6.
Vukovich M, Shiakolas A, Lindenberger J, Richardson R, Bass L, Barr M, et al.
PLoS Pathog
. 2024 Sep;
20(9):e1012499.
PMID: 39292703
Broadly reactive antibodies that target sequence-diverse antigens are of interest for vaccine design and monoclonal antibody therapeutic development because they can protect against multiple strains of a virus and provide...
7.
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs
Mu Z, Whitley J, Martik D, Sutherland L, Newman A, Barr M, et al.
J Virol
. 2024 Aug;
98(9):e0013724.
PMID: 39136461
Nucleoside-modified mRNA technology has revolutionized vaccine development with the success of mRNA COVID-19 vaccines. We used modified mRNA technology for the design of envelopes (Env) to induce HIV-1 broadly neutralizing...
8.
Zhang Q, Lindenberger J, Parsons R, Thakur B, Parks R, Park C, et al.
Mol Cell
. 2024 Jul;
84(14):2747-2764.e7.
PMID: 39059371
A recombinant lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant, named XBB, appeared in late 2022 and evolved descendants that successively swept local and global populations....
9.
Roark R, Habib R, Gorman J, Li H, Connell A, Bonsignori M, et al.
bioRxiv
. 2024 Jun;
PMID: 38903070
Highlights: Isolated 11 V2 apex-targeted HIV-neutralizing lineages from 10 SHIV-infected Indian-origin rhesus macaquesCryo-EM structures of Fab-Env complexes for nine rhesus lineages reveal modes of recognition that mimic three modes of...
10.
Pierre C, Adams L, Higgins J, Anasti K, Goodman D, Mielke D, et al.
PLoS Pathog
. 2024 Jun;
20(6):e1011569.
PMID: 38900807
Antibodies perform both neutralizing and non-neutralizing effector functions that protect against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 Spike N-terminal domain (NTD), DH1052, was recently shown to...